Researchers believe that a re-classification of NAFLD, which affects nearly a billion people globally with no drug treatment currently on the market, is essential to improve patient understanding and industry funding to better mitigate its impact.
Our teams joined virtually to hear the latest insights from regulators including the FDA, thought-leading scientists and translational and biomarker experts in drug development.